Mounjaro Generic: Is There One in 2026? Tirzepatide Patent Timeline

People search "Mounjaro generic" for two different reasons. Some want the generic name of the drug. Others want a cheap generic version they can fill instead of the brand. The answers are not the same, so let's settle both.

Direct answer: The generic name for Mounjaro is tirzepatide — that is the active ingredient. But there is no generic version of tirzepatide for sale in 2026. Eli Lilly's patents protect the molecule through January 5, 2036 (composition) and a formulation patent runs to June 14, 2039, so a true generic is not realistically expected in the US until the late 2030s. The most useful trick today is not a generic at all: the exact same molecule is sold as Zepbound for weight management, and Lilly prices Zepbound self-pay vials far below Mounjaro's list price.

Mounjaro Generic Name, Explained

This is the easy half of the question. Every drug has a brand name and a generic (nonproprietary) name. For Mounjaro:

So if a pharmacist, prescriber, or insurance form asks for the generic name of Mounjaro, the answer is tirzepatide. If anyone offers to sell you "generic Mounjaro" as a cheaper finished product, be skeptical — no FDA-approved generic exists, and what is being sold is either the brand, a compounded preparation, or something gray-market.

Why No Generic Tirzepatide Exists Yet

Mounjaro was FDA approved in May 2022, making tirzepatide a relatively new molecule. Generics can only enter once patent and exclusivity protection lapses, and Lilly has layered its patents to push that out as far as possible.

The composition patent expiring in 2036 is the floor. But the 2039 formulation patent means a generic maker would have to engineer around Lilly's specific formulation even after the molecule is free. That is why most patent analysts put the earliest realistic US generic launch in the late 2030s rather than 2036. A handful of other countries may see generic tirzepatide sooner where patent coverage is weaker, but that does not help US buyers.

The Real Money Move: Same Molecule, Cheaper Brand

Here is the part that actually lowers a bill in 2026. Mounjaro (diabetes) and Zepbound (weight loss) are the identical molecule, tirzepatide, at the identical doses. The difference is the label and the price strategy. Because many insurers do not cover weight-loss drugs, Lilly built a cash-pay channel for Zepbound — single-dose vials sold direct through LillyDirect:

This is the arbitrage: the same drug, same active ingredient, often far cheaper under the Zepbound label if you are paying cash. It is not a loophole or a generic — it is two brands of one molecule with two pricing models. Whether that switch is right for you depends on your indication and coverage; we lay out the full comparison in Mounjaro vs Zepbound. If you are insured and staying on Mounjaro for diabetes, the manufacturer card is usually the better lever — see Mounjaro coupon.

Want a lower price today? Yücca telehealth — online evaluation, doctor-prescribed compounded Tirzepatide+ or Semaglutide+ filled by a licensed US pharmacy, from $146/month. (Partner link: we may earn a commission, at no extra cost to you.)

What Happened to Compounded Tirzepatide

For a while, compounding pharmacies were the cheap "generic-ish" route. That door is mostly shut now. The FDA declared the tirzepatide shortage resolved in October 2024, and once a drug leaves the shortage list, large-scale compounding loses its legal footing. Enforcement discretion ended for 503B outsourcing facilities on March 19, 2025.

In 2026 the screws tightened further. On April 30, 2026, the FDA proposed excluding tirzepatide (along with semaglutide and liraglutide) from the 503B bulk-substance list, with comments open through June 29, 2026. The agency has issued more than 135 warning letters to compounders and telehealth sellers since September 2025. Narrow individualized 503A compounding survives only for a documented medical need that the brand cannot meet — not as a cheaper Mounjaro substitute. Details in compounded tirzepatide.

How Mounjaro Compares to the Rest of the Class

Mounjaro is not the only GLP-1 brand people search "generic" for, and the answers differ sharply across the class:

If your real goal is the lowest price for an effective GLP-1, the honest answer for tirzepatide is: there is no generic shortcut yet, so use the brand discount channels. For the one molecule where a true generic already exists, jump to Saxenda generic.

Frequently Asked Questions

What is the generic name for Mounjaro? Tirzepatide. It is the active ingredient in both Mounjaro and Zepbound.

Is there a generic for Mounjaro in 2026? No. Tirzepatide is still under patent — composition to January 2036 and formulation to June 2039 — so no FDA-approved generic exists, and none is expected until the late 2030s.

Is generic Mounjaro the same as Zepbound? They are the same molecule (tirzepatide) under two brand names, but neither is a "generic." Zepbound is the weight-loss brand and is often cheaper as a cash-pay self-pay vial.

Why is there no generic tirzepatide when Ozempic and Saxenda are talked about? Tirzepatide is newer and more heavily patented. Among GLP-1 brands, only Saxenda (liraglutide) has a true FDA-approved generic so far.

Can I get compounded tirzepatide instead? Generally no longer. The shortage ended in October 2024 and mass compounding is no longer permitted; only individualized 503A compounding for a documented medical need remains.

Last reviewed: June 13, 2026

Sources

• Mounjaro patent expiration — GreyB
• When do the patents on ZEPBOUND expire — DrugPatentWatch
• Lilly Reduces Price of Zepbound Single-Dose Vials for Self-Pay Patients — Pharmaceutical Executive
• FDA Moves to Shut the Door on Large-Scale Compounding of GLP-1 Drugs — Orrick